Hypercoagulable State in the Watanabe Heritable Hyperlipidemic Rabbit, an Animal Model for the Progression of Atherosclerosis

Yoshitaka Mori; Hideo Wada; Yutaka Nagano; Katsumi Deguch; Toru Kita; Shigeru Shirakawa

doi:10.1055/s-0038-1646543

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1989; 61(01): 140-143
DOI: 10.1055/s-0038-1646543

Original Article

Schattauer GmbH Stuttgart

Hypercoagulable State in the Watanabe Heritable Hyperlipidemic Rabbit, an Animal Model for the Progression of Atherosclerosis

Effect of Probucol on Coagulation

Authors

Yoshitaka Mori

^*The Second Department of Internal Medicine, Faculty of Medicine, Mie University, Japan
Hideo Wada

^*The Second Department of Internal Medicine, Faculty of Medicine, Mie University, Japan
Yutaka Nagano

^**The Third Department of Internal Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan
Katsumi Deguch

^*The Second Department of Internal Medicine, Faculty of Medicine, Mie University, Japan
Toru Kita

^**The Third Department of Internal Medicine, Faculty of Medicine, Kyoto University, Kyoto, Japan
Shigeru Shirakawa

^*The Second Department of Internal Medicine, Faculty of Medicine, Mie University, Japan

Abstract

PDF Download

Summary

Blood coagulation in a strain of rabbits designated as Watanabe heritable hyperlipidemic (WHHL) rabbits was examined. The activities of vitamin K-dependent clotting factors, contact factors and clotting factor VIII (F VIII) and the fibrinogen level were significantly higher in WHHL rabbits than in normolipidemic rabbits (all age groups). Values for vitamin Independent clotting factor were already higher at 2 months of age. Contact factors and fibrinogen levels increased age after 5 to 8 months. F VIII increased between 5 and 8 months and then decreased. At 2 months of age, WHHL rabbits were divided into two groups. Group A was fed standard rabbit chow and group B standard rabbit chow containing 1% probucol. Probucol prevented the progression of atherosclerosis in group B in the absence of a significant reduction in plasma cholesterol level. F VIII and fibrinogen levels were statistically decreased in all rabbits at all ages in group B (P<0.05). These differences in clotting factors between the two groups were most obvious at 8 months (P<0.02).

We conclude that vitamin K-dependent clotting factors may increase with hyperlipemia and that increases in F VIII and fibrinogen may be closely related to the progression of throm- boatherosclerosis.

Key words

Factor VIII - Fibrinogen - Watanabe heritable hyperlipidemic (WHHL) rabbit - Hypercholesterolemia - Atherosclerosis - Probucol

PDF (241 kb)

References

References
1 Goldstein JL, Kita T, Brown MS. Defective lipoprotein receptors and atherosclerosis. New Engl J Med 1983; 309: 288-296
2 Kita T, Brown MS, Watanabe Y, Goldstein JL. Deficiency of low density lipoprotein receptor in liver and adrenal gland of the WHHL rabbits. Proc Natl Acad Sci 1982; 79: 3623-3627
3 Watanabe Y. Serial inbreeding of rabbit with hereditary hyperlipidemia (WHHL)-incidence and development of atherosclerosis and Xanthoma. Atherosclerosis 1980; 36: 261-268
4 Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986; 77: 641-644
5 Baker SG, Joffe BI, Mendelsohn D, Seftel HC. Treatment of homozygous familial hypercholesterolaemia with probucol. A Afr Med J 1982; 62: 7-11
6 Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T. Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983; 48: 157-166
7 Harris RS, Gilmore HR, Bricker LA, Kiem IM, Rubin E. Longterm oral administration of probucol [4,4’-(Isopropylidenedithio) bis (2,6-di-t-Butylphenol)] (DH-581) in the management of hypercholesterolemia. J Am Geriatr Soc 1974; 22: 167-175
8 Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci 1987; 84: 5928-5931
9 Hardisty RM, Macpherson JC. A one-stage factor VIII (anti-haemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 1962; 7: 215-229
10 Foster JN T, Denatale A, Dotti LB. Determination of plasma fibrinogen by means of centrifugation after heating. Am J Clin Pathol 1959; 31: 42-45
11 Leffler HH, McDougald CH. Estimation of cholesterol in serum by means of improved technics. Tech Bull Regist Med Technol 1963; 33: 19-23
12 Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest 1975; 56: 1420-1430
13 Lowe GD O, Drummond MM, Third JL C H. et al Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinemia. Thromb Haemostas 1979; 42: 1503-1507
14 Sugrue DD, Trayner I, Thrompson GR, Vere VJ, Dimeson J, Stirling Y, Meade TW. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985; 53: 265-268
15 Noroy A, Brox JH, Holme S, Killie JE, Lenner RA. Platelets and coagulation in patients with familial hypercholesterolemia (type II). Acta Med Scand 1983; 213: 129-135
16 Elkeles RS, Chakrabarti R, Vickers M, Stirling Y, Meade TW. Effect of treatment of hyperlipidaemia on haemostatic variables. Br Med J 1980; 281: 973-974
17 Mari D, Vigotti G, Vergani C, Mannucci PM. Hemostatic functions in hypoalpha and hyperbetalipoproteinemias. Thromb Haemostas 1983; 50: 624-625
18 Simpson HC R, Mann JI, Meade TW, Chakrabarti R, Stirling Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 9: 786-789
19 Meade TW, North WR S, Chakrabarti R, Stirling Y, Haines AP, Thompson SG. Haemostatic function and cardiovascular death: Early results of a prospective study. The Lancet 1980; 17: 1050-1053
20 Kim WM, Mersky C, Deming QB, Adel HN, Wolinsky H, Clarkson TB, Lofland HB. Hyperlipidemia, hypercoagulability, and accelerated thrombosis: Studies in congenitally hyperlipidemic rats and in rats and monkeys with induced hyperlipidemia. Blood 1976; 47: 275-286
21 Constantino M, Merskey C, Kudzma DJ, Zucker MB. Increased activity of Vitamin K-dependent clotting factors in human hyperlipo- proteinaemia-association with cholesterol and triglyceride levels. Thromb Haemostas 1977; 38: 465-474
22 Cucuianu M, Popescu TA, Roman S, Bedeleanu D. Increased plasma level of clotting factors VII and X in hyperlipoproteinemia. Rev Roum Med 1985; 23: 37-43
23 Cucuianu M, Cristea A, Roman S, Missits I. Increased plasma antithrombin III level in hyperlipidemic subjects. Clin Chim Acta 1981; 110: 147-155
24 Hamilton PJ, Allardyce M, Ogston D, Dawson AA, Douglas AS. The effect of age upon the coagulation system. J Clin Pathol 1974; 27: 980-982
25 Dormandy JA, Hoare E, Colley J. Clinical, haemodynamic, rheological and biochemical findings in 126 patients with intermittent claudication. Br Med J 1973; 4: 576-581
26 Tanaka K, Sadoshima S. Fibrinogen and low density lipoprotein in the development of cerebral atherosclerosis. Atherosclerosis 1979; 34: 93-103
27 Fuster V, Bowie EJ W, Lewis JC, Fass DN, Owen CA, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand’s disease. J Clin Invest 1978; 61: 722-730
28 Fuster V, Fass DN, Kaye MP, Josa M, Zinsmeister AR, Bowie EJ W. Arteriosclerosis in normal and von Willebrand pigs. Long-term prospective study and aortic transplantation study Circ Res 1982; 51: 587-593